{
    "clinical_study": {
        "@rank": "72447", 
        "arm_group": {
            "arm_group_label": "Arm I", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive interleukin-12 IV over 5-15 seconds on day 1 and interferon alfa subcutaneously on days 2-6. Treatment repeats every 2 weeks in the absence of unacceptable toxicity. Patients are reassessed after 6 courses. Patients with a complete response receive 2 additional courses. Patients with a partial response or stable disease continue treatment in the absence of disease progression."
        }, 
        "brief_summary": {
            "textblock": "Phase II trial to study the effectiveness of combining interleukin-12 and interferon alfa in\n      treating patients who have metastatic malignant melanoma. Interleukin-12 may kill tumor\n      cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to\n      kill cancer cells. Interferon alfa may interfere with the growth of the cancer cells.\n      Combining interleukin-12 and interferon alfa may kill more tumor cells."
        }, 
        "brief_title": "Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma", 
        "condition": [
            "Recurrent Melanoma", 
            "Stage IV Melanoma"
        ], 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To estimate the clinical response rates in patients with metastatic malignant melanoma\n      treated with rhIL-12 and interferon alfa-2b.\n\n      II. To estimate the progression-free survival in patients with metastatic malignant melanoma\n      treated with rhIL-12 and interferon alfa-2b.\n\n      SECONDARY OBJECTIVES:\n\n      I. To measure serum levels of interferon-gamma. II. To measure levels of JAK-STAT signaling\n      intermediates in patient PBMCs and tumor samples.\n\n      III. To analyze interferon-alpha-induced STAT signaling in patient PBMCs. IV. To determine\n      the expression of IFN-regulated genes in patient PBMCs and tumor tissues.\n\n      V. To determine the pattern of gene expression induced by treatment with IL-12 and\n      interferon-alpha using DNA microarray techniques in patient PBMCs.\n\n      OUTLINE: This is a multicenter study.\n\n      Patients receive interleukin-12 IV over 5-15 seconds on day 1 and interferon alfa\n      subcutaneously on days 2-6. Treatment repeats every 2 weeks in the absence of unacceptable\n      toxicity. Patients are reassessed after 6 courses. Patients with a complete response receive\n      2 additional courses. Patients with a partial response or stable disease continue treatment\n      in the absence of disease progression.\n\n      Patients are followed every 3 months for 1 year and then every 6 months for 1 year."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histological or cytological diagnosis of cutaneous melanoma and clinical evidence of\n             distant, metastatic, non-resectable regional lymphatic, or extensive in transit\n             recurrent disease\n\n          -  Patients must have measurable disease; measurable disease is defined as the presence\n             of at least one measurable lesion; if the measurable disease is restricted to a\n             solitary lesion, its neoplastic nature should be confirmed by cytology/histology;\n             measurable lesions are defined as lesions that can be accurately measured in at least\n             one dimension with the longest diameter >= 20 mm using conventional techniques or >=\n             10 mm with spiral CT scan\n\n               -  Lesions that are considered intrinsically non-measurable include the following:\n\n                    -  Bone lesions;\n\n                    -  Leptomeningeal disease;\n\n                    -  Ascites;\n\n                    -  Pleural/pericardial effusion;\n\n                    -  Inflammatory breast disease;\n\n                    -  Lymphangitis cutis/pulmonis;\n\n                    -  Abdominal masses that are not confirmed and followed by imaging techniques;\n\n                    -  Lytic lesions;\n\n                    -  Lesions that are situated in a previously irradiated area\n\n          -  No history of peripheral neuropathy, brain metastases or other central nervous system\n             disease\n\n          -  No history of/active autoimmune disease, hemolytic anemia or concurrent requirement\n             for corticosteroids, including topical or inhaled\n\n          -  No hepatitis BSAg, known HIV disease or other major active illness; patients with\n             risk factors for HIV should be tested; patients with these illnesses are more likely\n             to experience significant side effects from the study treatment\n\n          -  No history of severe peptic ulcer disease or gastrointestinal bleeding unless there\n             is objective evidence that the condition is inactive or resolved\n\n          -  No uncontrolled or severe cardiovascular disease, diabetes, pulmonary disease, or\n             infection\n\n          -  No chemotherapy, radiotherapy, or anti-hormonal therapy within three weeks prior to\n             the initiation of therapy on this study\n\n          -  No prior therapy with IL-12\n\n          -  No prior therapy with IFN-alpha for metastatic disease (e.g., biochemotherapy); prior\n             adjuvant therapy with IFN-a is acceptable as long as the patient remained\n             disease-free for 12 months or longer following the last IFN-a treatment\n\n          -  No prior cytokine therapy for metastatic disease (e.g., high-dose IL-2)\n\n          -  No more than one prior chemotherapy regimen\n\n          -  CTC (ECOG) performance status 0-1\n\n          -  Non-pregnant, non-nursing; treatment under this protocol would expose an unborn child\n             to significant risks; women and men of reproductive potential should agree to use an\n             effective means of birth control; women of child-bearing age will undergo pregnancy\n             testing\n\n          -  ANC >= 1500/\u03bcL\n\n          -  Platelets >= 100,000/\u03bcL\n\n          -  Hemoglobin > 9 g/dL (may be post transfusion or may receive EPO)\n\n          -  U-HCG or Serum HCG Negative (if patient of child-bearing potential)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 9, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00026143", 
            "org_study_id": "NCI-2012-02816", 
            "secondary_id": [
                "CALGB-500001", 
                "CDR0000068990", 
                "U10CA031946"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm I", 
                "description": "Given IV", 
                "intervention_name": "recombinant interleukin-12", 
                "intervention_type": "Biological", 
                "other_name": [
                    "cytotoxic lymphocyte maturation factor", 
                    "IL-12", 
                    "interleukin-12", 
                    "natural killer cell stimulatory factor", 
                    "Ro 24-7472"
                ]
            }, 
            {
                "arm_group_label": "Arm I", 
                "description": "Given SC", 
                "intervention_name": "recombinant interferon alfa", 
                "intervention_type": "Biological", 
                "other_name": [
                    "Alferon N", 
                    "alpha interferon", 
                    "IFN-A", 
                    "Intron A", 
                    "Roferon-A"
                ]
            }, 
            {
                "arm_group_label": "Arm I", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferon Alfa-2a", 
                "Interferons", 
                "Interleukin-12"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 4, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chicago", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60606"
                }, 
                "name": "Cancer and Leukemia Group B"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Trial of Interleukin-12 (NSC #672423, IND #6798) Followed by Interferon Alfa-2B in Patients With Metastatic Malignant Melanoma", 
        "overall_official": {
            "affiliation": "Cancer and Leukemia Group B", 
            "last_name": "William Carson", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2004", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "PFS", 
                "safety_issue": "No", 
                "time_frame": "From registration until time of documented progression of disease or death from any cause, assessed up to 2 years"
            }
        ], 
        "removed_countries": {
            "country": "Puerto Rico"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00026143"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "October 2001", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }, 
    "geocoordinates": {
        "Cancer and Leukemia Group B": "41.878 -87.63"
    }
}